Lupus nephritis (LN) is one of the most serious complications of SLE, manifesting as haematuria and/or proteinuria, ...
Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) ...
Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer. Subgroup OS HR (95% CI) OS p-value ...
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and ...
MONTPELLIER, France--(BUSINESS WIRE)--Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed ...
New data from subgroup analyses of trials evaluating endovascular treatment in patients with stroke due to occlusions of distal or medium arteries has given some hope that there may be a population ...
Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, ...
Enlivex Therapeutics had a message Friday for investors who halved its share price: You’re misreading our data. The cell therapy developer blamed imbalances between cohorts for the mixed results—and ...
Rozanolixizumab effectively treats MuSK autoantibody-positive generalized myasthenia gravis, showing significant improvement in MG-ADL scores compared to placebo. MuSKgMG is more severe and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results